Roivant Sciences (NASDAQ:ROIV) Insider Frank Torti Sells 587,390 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 587,390 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $27.51, for a total value of $16,159,098.90. Following the sale, the insider directly owned 13,736,547 shares of the company’s stock, valued at $377,892,407.97. This represents a 4.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Frank Torti also recently made the following trade(s):

• On Thursday, February 19th, Frank Torti sold 1,400,000 shares of Roivant Sciences stock. The shares were sold at an average price of $27.42, for a total value of $38,388,000.00.
• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.

Roivant Sciences Stock Up 2.2%

NASDAQ:ROIV opened at $27.76 on Tuesday. The company has a fifty day moving average of $23.44 and a 200-day moving average of $19.07. The firm has a market capitalization of $19.87 billion, a P/E ratio of -23.73 and a beta of 1.22. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $27.94.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ROIV shares. Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. HC Wainwright upped their price target on Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, February 10th. Guggenheim raised their price objective on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a report on Saturday, February 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.69.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ROIV. Oregon Public Employees Retirement Fund grew its holdings in Roivant Sciences by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 87,152 shares of the company’s stock worth $1,891,000 after buying an additional 500 shares in the last quarter. Bank of Montreal Can lifted its stake in Roivant Sciences by 1.3% during the 4th quarter. Bank of Montreal Can now owns 40,012 shares of the company’s stock valued at $868,000 after acquiring an additional 516 shares in the last quarter. Bessemer Group Inc. boosted its holdings in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Allworth Financial LP grew its stake in shares of Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares in the last quarter. Finally, Fifth Third Bancorp grew its stake in shares of Roivant Sciences by 15.8% in the 4th quarter. Fifth Third Bancorp now owns 4,310 shares of the company’s stock worth $94,000 after acquiring an additional 588 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.